KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to $2.0 billion.

  • Boston Scientific's Cash & Equivalents rose 37463.77% to $2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 37463.77%. This contributed to the annual value of $2.0 billion for FY2025, which is 37463.77% up from last year.
  • Boston Scientific's Cash & Equivalents amounted to $2.0 billion in Q4 2025, which was up 37463.77% from $1.3 billion recorded in Q3 2025.
  • Boston Scientific's Cash & Equivalents' 5-year high stood at $2.9 billion during Q2 2024, with a 5-year trough of $276.0 million in Q2 2022.
  • In the last 5 years, Boston Scientific's Cash & Equivalents had a median value of $940.0 million in 2022 and averaged $1.3 billion.
  • In the last 5 years, Boston Scientific's Cash & Equivalents tumbled by 8968.22% in 2022 and then soared by 58380.28% in 2024.
  • Boston Scientific's Cash & Equivalents (Quarter) stood at $1.9 billion in 2021, then tumbled by 51.79% to $928.0 million in 2022, then dropped by 6.79% to $865.0 million in 2023, then crashed by 52.14% to $414.0 million in 2024, then skyrocketed by 374.64% to $2.0 billion in 2025.
  • Its last three reported values are $2.0 billion in Q4 2025, $1.3 billion for Q3 2025, and $534.0 million during Q2 2025.